218451-56-0 Usage
Uses
Used in Pharmaceutical Industry:
1-(amino(3,4-difluorophenyl)methyl)cyclobutanol is used as a potential active pharmaceutical ingredient (API) for its possible antiviral and anti-inflammatory properties. The cyclobutanol ring in the compound has been associated with these biological activities, making it a promising candidate for the development of new drugs targeting viral and inflammatory diseases.
Used in Medicinal Chemistry:
1-(amino(3,4-difluorophenyl)methyl)cyclobutanol is used as a structural motif in the design of new drugs due to the influence of the fluorine atoms in the difluorophenyl group. The presence of fluorine often enhances the compound's pharmacokinetic and pharmacodynamic properties, such as increasing its lipophilicity, metabolic stability, and bioavailability, which are crucial factors in drug development.
Used in Drug Design and Optimization:
1-(amino(3,4-difluorophenyl)methyl)cyclobutanol is used as a starting point for the design and optimization of new drug candidates. Its unique structure and potential biological activities make it an attractive template for further chemical modifications and improvements to enhance its therapeutic potential and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 218451-56-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,1,8,4,5 and 1 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 218451-56:
(8*2)+(7*1)+(6*8)+(5*4)+(4*5)+(3*1)+(2*5)+(1*6)=130
130 % 10 = 0
So 218451-56-0 is a valid CAS Registry Number.
218451-56-0Relevant academic research and scientific papers
Oxazolidinones as alpha 1A receptor antagonists
-
, (2008/06/13)
This invention is directed to oxazolidinone compounds which are selective antagonists for human alpha 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the alpha 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
